ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

76

BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference held from June 15-18, 2019 in Gothenburg, Sweden. Presentation Details: Title:     An open-label, phase 1/2 study of miransertib (ARQ 092…

 

 

 

 

http://www.businesswire.com/news/home/20190610005186/en/ArQule-Announces-Oral-Presentation-Pan-AKT-Inhibitor-Miransertib